NCT04505098View on ClinicalTrials.gov

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

PHASE4TerminatedINTERVENTIONAL

Enrollment

39,600

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions

Covid19AtherosclerosisCardiovascular DiseasesUpper Respiratory Tract Infections

Interventions

DRUG

Icosapent ethyl

2 g by mouth twice daily for at least 6 months

Trial Locations (1)

94612

Division of Research, Oakland

Sponsors

Collaborators (1)

Amarin Corporation

All Listed Sponsors

collaborator

Amarin Corporation

UNKNOWN

lead

Kaiser Permanente

OTHER